ATE488224T1 - Aerosol-formulierungen von diisobutyryl apomorphine - Google Patents

Aerosol-formulierungen von diisobutyryl apomorphine

Info

Publication number
ATE488224T1
ATE488224T1 AT03743339T AT03743339T ATE488224T1 AT E488224 T1 ATE488224 T1 AT E488224T1 AT 03743339 T AT03743339 T AT 03743339T AT 03743339 T AT03743339 T AT 03743339T AT E488224 T1 ATE488224 T1 AT E488224T1
Authority
AT
Austria
Prior art keywords
aerosol formulations
diisobutyryl
apomorphine
diisobutyryl apomorphine
aerosol
Prior art date
Application number
AT03743339T
Other languages
English (en)
Inventor
Rebecca Davies
David Ganderton
David Lewis
Brian Meakin
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE488224T1 publication Critical patent/ATE488224T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03743339T 2002-03-01 2003-02-26 Aerosol-formulierungen von diisobutyryl apomorphine ATE488224T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (de) 2002-03-01 2002-03-01 Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
PCT/EP2003/001962 WO2003074023A1 (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Publications (1)

Publication Number Publication Date
ATE488224T1 true ATE488224T1 (de) 2010-12-15

Family

ID=27675679

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743339T ATE488224T1 (de) 2002-03-01 2003-02-26 Aerosol-formulierungen von diisobutyryl apomorphine

Country Status (27)

Country Link
US (1) US20050129621A1 (de)
EP (2) EP1340492A1 (de)
JP (1) JP2005519094A (de)
KR (1) KR20040091050A (de)
CN (2) CN1638731A (de)
AR (2) AR038643A1 (de)
AT (1) ATE488224T1 (de)
AU (1) AU2003215597B2 (de)
BR (1) BR0303348A (de)
CA (1) CA2477879C (de)
DE (1) DE60334973D1 (de)
EA (1) EA008571B1 (de)
ES (1) ES2358293T3 (de)
GE (1) GEP20063985B (de)
HR (1) HRP20040751A2 (de)
IL (1) IL163842A0 (de)
MA (1) MA27107A1 (de)
MX (1) MXPA04008370A (de)
NO (1) NO20034874L (de)
NZ (1) NZ535019A (de)
PE (1) PE20030949A1 (de)
PL (1) PL372261A1 (de)
TN (1) TNSN04148A1 (de)
TW (1) TW200304833A (de)
UA (2) UA81238C2 (de)
WO (1) WO2003074023A1 (de)
ZA (3) ZA200406918B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EE05167B1 (et) * 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
EP1415647A1 (de) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
EP1452179A1 (de) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
KR20060117909A (ko) * 2003-09-15 2006-11-17 벡투라 리미티드 폐 흡입에 의한 조루 치료용 제약학적 조성물
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
BRPI0512878A (pt) * 2004-07-02 2008-04-15 Boehringer Ingelheim Int formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor
RU2457832C2 (ru) * 2005-09-25 2012-08-10 Сипла Лимитед Состав на основе тровентола
WO2007076053A2 (en) * 2005-12-21 2007-07-05 Nitrox, Llc Stable s-nitrosothiol formulations
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (de) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Aktuator für einen Inhalator für abgemessene Dosen
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
MX336260B (es) * 2010-07-12 2016-01-13 Xellia Pharmaceuticals Aps Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
WO2012039741A1 (en) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof
EP2717855A4 (de) 2011-06-07 2014-11-12 Parion Sciences Inc Behandlungsverfahren
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US20130156823A1 (en) * 2011-12-20 2013-06-20 MAP Pharmacauticals, Inc. Excipient-free Aerosol Formulation
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
EP3160445B1 (de) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi-verwandte produkte und verfahren zur verwendung
EP3297710A4 (de) * 2015-05-21 2019-05-01 Island Breeze Systems Ca, LLC Treibmittelbasierter inhalator mit abgemessener dosis sowie lebensmittelapplikatoren und applikatoren
US11129848B2 (en) 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof
JP2024515446A (ja) * 2021-03-23 2024-04-10 1232176 ビー.シー. リミテッド アナフィラキシーを処置するためのデバイス

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024420A1 (en) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
IT1317904B1 (it) * 1999-09-11 2003-07-15 Glaxo Group Ltd Formulazione farmaceutica di propionato di fluticasone.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
CZ303537B6 (cs) * 2000-03-09 2012-11-21 Gw Pharma Limited Použití konopí pri príprave farmaceutické formulace a pumpickové sprejové zarízení
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
EE05167B1 (et) * 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
EP1595531A1 (de) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren

Also Published As

Publication number Publication date
DE60334973D1 (de) 2010-12-30
ES2358293T3 (es) 2011-05-09
CA2477879A1 (en) 2003-09-12
AU2003215597B2 (en) 2008-07-31
MXPA04008370A (es) 2004-11-26
EP1340492A1 (de) 2003-09-03
PE20030949A1 (es) 2004-01-02
ZA200406918B (en) 2006-06-28
TNSN04148A1 (en) 2007-03-12
EP1480616A1 (de) 2004-12-01
WO2003074023A1 (en) 2003-09-12
JP2005519094A (ja) 2005-06-30
MA27107A1 (fr) 2004-12-20
UA81238C2 (en) 2007-12-25
CA2477879C (en) 2011-05-03
GEP20063985B (en) 2006-12-11
KR20040091050A (ko) 2004-10-27
CN1638731A (zh) 2005-07-13
TW200304833A (en) 2003-10-16
ZA200406917B (en) 2006-06-28
NO20034874L (no) 2003-12-23
NO20034874D0 (no) 2003-10-31
AR101593A2 (es) 2016-12-28
UA80695C2 (en) 2007-10-25
HRP20040751A2 (en) 2004-12-31
IL163842A0 (en) 2005-12-18
US20050129621A1 (en) 2005-06-16
AR038643A1 (es) 2005-01-19
EP1480616B1 (de) 2010-11-17
NZ535019A (en) 2006-09-29
PL372261A1 (en) 2005-07-11
AU2003215597A1 (en) 2003-09-16
EA200401006A1 (ru) 2005-04-28
ZA200406919B (en) 2006-06-28
EA008571B1 (ru) 2007-06-29
BR0303348A (pt) 2004-07-13
CN101502500A (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
DE60334973D1 (de) Aerosol-formulierungen von diisobutyryl apomorphine
EP1583997A4 (de) Photoresistentfernung
DE60332036D1 (de) Einteilige hand-airbrush
NO20044916L (no) Preparater av sulfinylacetamid
PT1513514E (pt) Formulações tópicas de hidroximatairesinol
IS7407A (is) Afleysing lausnarsambanda atorvastatínhálfkalsíums
ITMI20021038A0 (it) Disposizione di elettrodi
DE60327426D1 (de) Markierung von substraten
DE60323088D1 (de) Leberschützende wirkung der 10-o-p-hydroxybenzoylaucubin
FR2834647B1 (fr) Putter
UA6687S (uk) Комплект етикеток
UA6800S (uk) Комплект етикеток
UA6562S (uk) Комплект етикеток
UA6563S (uk) Комплект етикеток
UA6798S (uk) Комплект етикеток
UA6303S (uk) Комплект етикеток
UA7077S (uk) Комплект етикеток
UA6561S (uk) Комплект етикеток
UA7370S (uk) Комплект етикеток
UA6801S (uk) Комплект етикеток
UA6799S (uk) Комплект етикеток
UA6680S (uk) Комплект етикеток
UA6675S (uk) Комплект етикеток
SE0202115D0 (sv) Use of a composition
FI20020094A7 (fi) Nefriinintapaisten yhdisteiden käyttö

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1480616

Country of ref document: EP